{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"98"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"200"}],"units":"Participants"}],"description":"Objective Response Rate (ORR) is defined as the percentage of patients that achieve a best overall response \\[complete response (CR) or partial response (PR)\\] evaluated according to the mRECIST v1.1 across all post-randomization time-points until the end of protocol treatment. Confirmation of response will not be required.","groups":[{"description":"Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\\^2 intravenously on day 1 every 3 weeks","id":"OG000","title":"Atezolizumab Plus Bevacizumab Plus Chemotherapy"},{"description":"Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\\^2 intravenously on day 1 every 3 weeks","id":"OG001","title":"Bevacizumab Plus Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Efficacy population (Intention-To-Treat cohort of all randomised patients)","reportingStatus":"POSTED","timeFrame":"From randomization to termination of trial treatment, up to 52 months.","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}